An overview on the development of new potentially active camptothecin analogs against cancer
Eliza de Lucas Chazin, Raisa da Rocha Reis, Walcimar Trindade Vellasco Junior
1Universidade Federal Fluminense, Instituto de Quimica, Programa de Pos-Graduacao em Quimica, Outeiro de Sao Joao Batista, s/nº, Centro, Niteroi, 24020-141, Rio de Janeiro, Brazil. gqothatyana@vm.uff.br.
Abstract:
Camptothecin (CPT) and its derivatives comprise an important group of heterocyclic compounds that are well recognized for their anticancer activities. Efforts have been made over the years aiming to develop new CPT analogs with better clinical efficacy, improved pharmacokinetic profile and lower toxicity. First generation of analogs, irinotecan (CPT-11) and topotecan (TPT) was approved for use by FDA in 1996 for the treatment of colorectal (CPT-11) and cervical, ovarian and small lung cancers (TPT). Other analogs of CPT are currently in different phases of clinical trials. As CPT represents an important lead compound in the field of antitumor- research, in this review we will highlight some recent discoveries (2008-2013) on the development of novel camptothecin-based compounds as potential anticancer agents.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules
Treatment Resistant Cancers
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


